Leerink Partnrs upgraded shares of CVS Health (NYSE:CVS - Free Report) from a hold rating to a strong-buy rating in a research note released on Wednesday morning,Zacks.com reports. Leerink Partnrs also issued estimates for CVS Health's FY2027 earnings at $8.23 EPS and FY2028 earnings at $9.36 EPS.
A number of other equities research analysts have also recently commented on CVS. Piper Sandler lowered their price objective on shares of CVS Health from $72.00 to $64.00 and set an "overweight" rating on the stock in a research note on Monday, November 25th. TD Cowen increased their price target on shares of CVS Health from $73.00 to $80.00 and gave the company a "buy" rating in a research report on Monday, November 25th. Royal Bank of Canada cut their price objective on CVS Health from $68.00 to $58.00 and set an "outperform" rating for the company in a research report on Friday, November 15th. UBS Group lowered their target price on CVS Health from $62.00 to $59.00 and set a "neutral" rating on the stock in a report on Tuesday, February 11th. Finally, Mizuho cut their price target on CVS Health from $73.00 to $66.00 and set an "outperform" rating for the company in a report on Thursday, October 24th. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, CVS Health currently has a consensus rating of "Moderate Buy" and a consensus target price of $70.28.
Check Out Our Latest Research Report on CVS
CVS Health Price Performance
Shares of CVS traded down $0.67 during trading hours on Wednesday, reaching $65.71. The company had a trading volume of 10,208,186 shares, compared to its average volume of 12,149,901. The company has a current ratio of 0.80, a quick ratio of 0.59 and a debt-to-equity ratio of 0.80. CVS Health has a 12-month low of $43.56 and a 12-month high of $80.75. The firm has a 50 day simple moving average of $51.11 and a 200-day simple moving average of $55.99. The company has a market capitalization of $82.84 billion, a price-to-earnings ratio of 16.68, a PEG ratio of 0.60 and a beta of 0.61.
CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 EPS for the quarter, topping the consensus estimate of $0.89 by $0.30. CVS Health had a return on equity of 10.72% and a net margin of 1.36%. Research analysts expect that CVS Health will post 5.14 earnings per share for the current year.
CVS Health Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Monday, February 3rd. Shareholders of record on Thursday, January 23rd were given a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 4.05%. The ex-dividend date of this dividend was Thursday, January 23rd. CVS Health's dividend payout ratio (DPR) is presently 72.68%.
Institutional Trading of CVS Health
Several large investors have recently bought and sold shares of the company. Norges Bank acquired a new position in shares of CVS Health in the 4th quarter valued at approximately $839,574,000. Capital World Investors increased its stake in shares of CVS Health by 26.6% in the fourth quarter. Capital World Investors now owns 61,039,777 shares of the pharmacy operator's stock worth $2,739,927,000 after buying an additional 12,819,148 shares during the last quarter. Davis Selected Advisers raised its holdings in CVS Health by 2,998.1% in the fourth quarter. Davis Selected Advisers now owns 11,385,950 shares of the pharmacy operator's stock valued at $511,115,000 after acquiring an additional 11,018,438 shares in the last quarter. Dodge & Cox boosted its stake in CVS Health by 11.2% during the 4th quarter. Dodge & Cox now owns 70,105,899 shares of the pharmacy operator's stock valued at $3,147,054,000 after acquiring an additional 7,075,209 shares during the last quarter. Finally, Pzena Investment Management LLC grew its holdings in CVS Health by 49.3% during the 4th quarter. Pzena Investment Management LLC now owns 19,610,579 shares of the pharmacy operator's stock worth $880,319,000 after acquiring an additional 6,475,271 shares in the last quarter. Institutional investors and hedge funds own 80.66% of the company's stock.
CVS Health Company Profile
(
Get Free Report)
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
See Also
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
